The proliferation of vascular SMCs, the second major cell type involved in post-stroke angiogenesis, was modulated by several “new-for-stroke” genes including the pro-angiogenic factors lymphoid enhancer-binding factor 1 (Lef1), transgelin (Tagln), wingless-type MMTV integration site family, member 4 (Wnt4a) but also by the well-known matrix metallopeptidase 2 (Mmp2). This evidence concerns the gene MMP2 and stroke disorder.